46,300 Shares in SI-Bone Inc (SIBN) Purchased by Spark Investment Management LLC
Spark Investment Management LLC bought a new stake in SI-Bone Inc (NASDAQ:SIBN) in the first quarter, HoldingsChannel.com reports. The institutional investor bought 46,300 shares of the company’s stock, valued at approximately $872,000.
A number of other institutional investors have also added to or reduced their stakes in SIBN. Valeo Financial Advisors LLC purchased a new stake in shares of SI-Bone during the first quarter valued at $94,000. Deutsche Bank AG purchased a new stake in SI-Bone in the 4th quarter worth about $227,000. Geode Capital Management LLC purchased a new stake in SI-Bone in the 4th quarter worth about $1,972,000. Millennium Management LLC purchased a new stake in SI-Bone in the 4th quarter worth about $3,362,000. Finally, RTW Investments LP purchased a new stake in SI-Bone in the 4th quarter worth about $16,802,000. 37.92% of the stock is owned by institutional investors.
Shares of SI-Bone stock opened at $16.29 on Wednesday. The stock has a market capitalization of $400.15 million and a P/E ratio of -22.94. The company has a debt-to-equity ratio of 0.47, a current ratio of 13.06 and a quick ratio of 14.73. SI-Bone Inc has a 1 year low of $14.08 and a 1 year high of $23.03.
In other SI-Bone news, CFO Laura Francis sold 2,000 shares of the company’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $15.96, for a total value of $31,920.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Mark A. Reiley sold 10,000 shares of the company’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $16.95, for a total value of $169,500.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 24,949 shares of company stock worth $411,841.
Several brokerages recently issued reports on SIBN. Zacks Investment Research raised SI-Bone from a “sell” rating to a “hold” rating in a research note on Tuesday, March 26th. ValuEngine downgraded SI-Bone from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. SI-Bone has an average rating of “Buy” and a consensus price target of $24.75.
SI-Bone Company Profile
SI-BONE, Inc, a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.
Recommended Story: Gross Domestic Product (GDP)
Want to see what other hedge funds are holding SIBN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SI-Bone Inc (NASDAQ:SIBN).
Receive News & Ratings for SI-Bone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-Bone and related companies with MarketBeat.com's FREE daily email newsletter.